COMPANY RESEARCHBiocytogen Pharmaceuticals (Beijing) Co. Ltd.
Biocytogen is a Beijing-headquartered biotechnology company developing platforms and therapeutic antibody assets for drug discovery and collaborative development. Its RenMice and related antibody technologies support fully human antibodies, multispecific formats and antibody-drug conjugate programs. The business also supplies research models and preclinical services, but its disclosed agreements include therapeutic antibody co-development and out-licensing, so it should not be categorized as a pure contract research provider. Biocytogen has public share listings on the Shanghai Stock Exchange STAR Market and the Hong Kong Stock Exchange.
Company at a glance
Corporate information
- Company entity
- 百奥赛图（北京）医药科技股份有限公司
- Headquarters / principal office
- Waltham, MassachusettsSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.
Sources (1)
- Company-managed LinkedIn profile — self-reported locationChecked 2026-11-04; source publication date retained where stated
- Founded
- 2009 (Beijing listed entity); group origins in 2008
Sources (1)
- 百奥赛图（北京）医药科技股份有限公司2025年年度报告2026-03-27
- Ownership / capital status
- Publicly tradedPublicly traded (SSE:688796 / HKEX:02315)
Sources (2)
- 百奥赛图（北京）医药科技股份有限公司2026年第三季度报告2026-10-30
- 百奥赛图（北京）医药科技股份有限公司2025年年度报告2026-03-27
- Official corporate reference
- https://biocytogen.com.cn/
Sources (2)
- 公司官网 / About / 发展历程Not stated
- 百奥赛图（北京）医药科技股份有限公司2025年年度报告2026-03-27
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Biocytogen — official company page2026-11-04 retrieval; page undated unless stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
SSE STAR: 688796 HKEX: 02315
fully human antibody discovery · bispecific antibodies · antibody-drug conjugates
oncology · immunology
Last independently verified:
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Biocytogen is a Beijing-headquartered biotechnology company developing platforms and therapeutic antibody assets for drug discovery and collaborative development. Its RenMice and related antibody technologies support fully human antibodies, multispecific formats and antibody-drug conjugate programs. The business also supplies research models and preclinical services, but its disclosed agreements include therapeutic antibody co-development and out-licensing, so it should not be categorized as a pure contract research provider. Biocytogen has public share listings on the Shanghai Stock Exchange STAR Market and the Hong Kong Stock Exchange.
Business, technology & evidence
- SecuritiesSSE STAR: 688796 / HKEX: 02315
- Combines gene-edited animal-model products and preclinical services with RenMice antibody discovery, licensing/transfers, and collaborative development.
- Listed as SSE 688796 / HKEX 02315; original 2025 annual and 2026Q3 (YTD) reports reviewed.
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Financials are consolidated figures for the listed group. Revenue by service line, available capacity, and project fit require further verification at the segment and operating-entity levels.
- Proprietary products/licensing and research services operate in parallel. Distinguish business lines; group profit does not establish the quality of a specific service.
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ↗Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ·
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ↗Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ·
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ↗Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ·
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ↗Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ·
- Official issuer and R&D disclosure · Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ↗Biocytogen Pharmaceuticals (Beijing) Co. Ltd. ·
- 百奥赛图（北京）医药科技股份有限公司2026年第三季度报告 ↗百奥赛图 · 2026-10-30
- 百奥赛图（北京）医药科技股份有限公司2025年年度报告 ↗百奥赛图 · 2026-03-27
- 公司官网 / About / 发展历程 ↗百奥赛图（北京）医药科技股份有限公司 · Not stated
- Company LinkedIn 页面 ↗LinkedIn / 百奥赛图（北京）医药科技股份有限公司 · Not stated
- Biocytogen — official company page ↗Biocytogen · 2026-11-04 retrieval; page undated unless stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.